PremiumCompany AnnouncementsPercheron Therapeutics Restructures R&D Focus Amidst Strategic Shift Percheron Therapeutics Retains Board with Strong Shareholder Support Percheron Therapeutics Sees Major Shift in Shareholder Structure PremiumCompany AnnouncementsPercheron Therapeutics Board Opposes Proposed Resolutions Percheron Therapeutics Addresses ASX Inquiry on Director’s Share Trading Percheron Therapeutics Announces Change in Substantial Holders PremiumCompany AnnouncementsPercheron Therapeutics to Present Promising Phase IIb Trial Results Percheron Therapeutics Announces Cessation of Securities Percheron Therapeutics Reassesses Strategy Following Avicursen Study Outcome